. 27. Boivin G, Lips P, Ott SM, et al. Contribution of raloxifene and calcium and vitamin D3 supplementation for the raise of your degree of mineralization of bone in postmenopausal females. J Clin Endocrinol Metab. 2003;88(9):4199205. 28. Nakamura T, Liu JL, Morii H, et al. Effect of raloxifene on clinical fractures in Asian girls with postmenopausal osteoporosis. J Bone Miner Metab. 2006;24(five):41418. 29. Gorai I, Tanaka Y, Hattori S, Iwaoki Y. Assessment of adherence to therapy of postmenopausal osteoporosis with raloxifene and/or alfacalcidol in postmenopausal Japanese girls. J Bone Miner Metab. 2010;28(2):17684. 30. Ando H, Otoda T, Ookami H, et al. Dosing time-dependent effect of raloxifene on plasma plasminogen activator inhibitor-1 concentrations in post-menopausal women with osteoporosis. Clin Exp Pharmacol Physiol. 2013;40(three):22732. 31. Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H. Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly girls with osteoporosis. Yonsei Med J. 29 2008;49(1):11928. 32. Gorai I, Hattori S, Tanaka Y, Iwaoki Y. Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifenealone therapy in postmenopausal Japanese girls with osteoporosis or osteopenia. J Bone Miner Metab. 2012;30(three):34958. 33. Majima T, Komatsu Y, Shimatsu A, et al. Efficacy of combined therapy with raloxifene and alfacalcidol on bone density and biochemical markers of bone turnover in postmenopausal osteoporosis. Endocr J. 2008;55(1):12734. 34. Hayashi T, Ina K, Maeda M, Nomura H. The effects of selective estrogen receptor modulator treatment following hormone replacement therapy on elderly postmenopausal girls with osteoporosis. Nitric Oxide. 2011;24(4):19903. 35. Morii H, Ohashi Y, Taketani Y, et al. Impact of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal girls with osteoporosis: outcomes from a randomized placebo-controlled trial. Osteoporos Int. 2003;14(ten):79300.MDS, and Pfizer. MS is definitely an employee of Eli Lilly Japan K.K.; PGC is an employee of Eli Lilly Australia; JAF and RB are personnel of Eli Lilly and Business; all are stock stockholders in Eli Lilly and Corporation. EH was an employee of Eli Lilly Japan K.K. when this manuscript was developed.Tempol Autophagy EH is presently an employee of Amgen Astellas Biopharma K.Bivatuzumab Epigenetics K.PMID:24456950 1. [No authors listed]. Who’re candidates for prevention and therapy for osteoporosis Osteoporos Int. 1997;7(1):1. two. Yoshimura N, Muraki S, Oka H, et al. Prevalence of knee osteoarthritis, lumbar spondylosis, and osteoporosis in Japanese males and ladies: the study on osteoarthritis/osteoporosis against disability study. J Bone Miner Metab. 2009;27(five):62028. three. United Nations. Planet Mortality Report 2011. New York: UN; 2012. Offered from: http://www.un.org/esa/population/publications/world mortalityreport2011/World 20Mortality 20Report 202011.pdf. Accessed June 13, 2013. 4. Statistics Japan. Existing population estimates as of October 1, 2012. Out there from: http://www.stat.go.jp/english/data/jinsui/2012np/ index.htm. Accessed June 13, 2013. five. Marshall D, Johnell O, Wedel H. Meta-analysis of how nicely measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312(7041):1254259. six. Briggs AM, Greig AM, Wark JD. The vertebral fracture cascade in osteoporosis: a assessment of aetiopathogenesis. Osteoporos Int. 2007; 18(five):57584. 7. Klotzb.
